quavonlimab,lenvatinib,favezelimab,pembrolizumab
eisai,merck
['pembro']
coming soon? combining t cell inflammatory profiling w pd-l1 tps and tmb- tantalizing hints that we can enhance io for certain groups (do t cell inflamed/tmb low benefit from pembro + vegfr antagonist? maybe ). #sitc22 